PMID- 36915396
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230315
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 16
DP  - 2023
TI  - Comparison of Plasma Exosome Proteomes Between Obese and Non-Obese Patients with 
      Type 2 Diabetes Mellitus.
PG  - 629-642
LID - 10.2147/DMSO.S396239 [doi]
AB  - PURPOSE: Obesity is considered a promoter of type 2 diabetes mellitus (T2DM). 
      However, the underlying mechanism remains unclear. This study aimed to identify 
      plasma exosome differentially expressed proteins (DEPs) that are potentially 
      involved in the development of obesity-related T2DM. METHODS: Exosomes were 
      isolated from the plasma of obese and non-obese T2DM patients (n = 10 for each 
      group). A label-free quantitative mass spectrometry analysis was applied to 
      identify plasma exosome DEPs in obese patients compared with non-obese patients, 
      followed by bioinformatics analysis including GO annotation, KEGG analysis, 
      subcellular localization prediction, transcription factor analysis, and 
      protein-protein interaction (PPI) prediction. RESULTS: We identified 2 
      significantly upregulated proteins (C9 and PON1) and 5 significantly 
      downregulated proteins (HPX, A1BG, CFHR1, ANG, and CALM) in obese patients 
      compared with those in non-obese patients. KEGG analysis demonstrated that the 
      insulin signaling pathway was one of the pathways that significantly correlated 
      with the DEPs. The DEPs were primarily localized in the extracellular space (5 
      out of 7). HMG-box and NF-Y beta might regulate the transcription of the DEPs. 
      C9, PON1, HPX, and CFHR1 were present in the PPI network. CONCLUSION: The plasma 
      exosome DEPs are potentially responsible for the development of obesity-related 
      T2DM possibly through the insulin signaling pathway and the interaction with 
      other proteins. Our study may guide future research direction toward the 
      pathogenesis of obesity-related T2DM.
CI  - (c) 2023 Wang et al.
FAU - Wang, Yanjun
AU  - Wang Y
AD  - Department of Endocrinology, The Second Hospital of Jilin University, Changchun, 
      People's Republic of China.
FAU - Wu, You
AU  - Wu Y
AD  - Department of Endocrinology, The Second Hospital of Jilin University, Changchun, 
      People's Republic of China.
FAU - Yang, Shuangzhu
AU  - Yang S
AD  - Department of Endocrinology, The Second Hospital of Jilin University, Changchun, 
      People's Republic of China.
FAU - Chen, Yan
AU  - Chen Y
AUID- ORCID: 0000-0001-9302-3962
AD  - Department of Endocrinology, The Second Hospital of Jilin University, Changchun, 
      People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20230307
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC10008006
OTO - NOTNLM
OT  - exosomes
OT  - insulin resistance
OT  - mass spectrometry
OT  - obesity
OT  - proteomics
OT  - type 2 diabetes mellitus
COIS- The authors declare that they have no competing interests in this work.
EDAT- 2023/03/15 06:00
MHDA- 2023/03/15 06:01
PMCR- 2023/03/07
CRDT- 2023/03/14 02:06
PHST- 2022/11/11 00:00 [received]
PHST- 2023/02/24 00:00 [accepted]
PHST- 2023/03/14 02:06 [entrez]
PHST- 2023/03/15 06:00 [pubmed]
PHST- 2023/03/15 06:01 [medline]
PHST- 2023/03/07 00:00 [pmc-release]
AID - 396239 [pii]
AID - 10.2147/DMSO.S396239 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2023 Mar 7;16:629-642. doi: 10.2147/DMSO.S396239. 
      eCollection 2023.